Advocacy at a Glance 1/22/21 Advocacy at a Glance 1/22/21 Dr. Woodcock is the new Acting Commissioner. Alliance members and other FDA stakeholders are encouraged to express thanks to Congress for supporting FDA. Read More Analysis and Commentary 10/24/20 Analysis and Commentary 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More Analysis and Commentary 10/16/20 Analysis and Commentary 10/16/20 Future Changes in Congressional Committees and the FDA Read More Analysis and Commentary 5/1/20 Analysis and Commentary 5/1/20 No Need for a Crystal Ball in Some Scenarios Read More Advocacy at a Glance 3/27/20 Advocacy at a Glance 3/27/20 Advocacy at a Glance Read More Analysis and Commentary 9/30/19 Analysis and Commentary 9/30/19 "Wouldn't It Be Wonderful" Read More Advocacy at a Glance 3/22/19 Advocacy at a Glance 3/22/19 Advocacy at a Glance Read More Advocacy at a Glance 1/19/17 Advocacy at a Glance 1/19/17 Advocacy at a Glance Read More Advocacy at a Glance 11/7/16 Advocacy at a Glance 11/7/16 Advocacy at a Glance Read More Analysis and Commentary 10/30/15 Analysis and Commentary 10/30/15 So ... How Do We Help FDA Get a Fair Cut of the Extra $40 Billion? Read More
Advocacy at a Glance 1/22/21 Advocacy at a Glance 1/22/21 Dr. Woodcock is the new Acting Commissioner. Alliance members and other FDA stakeholders are encouraged to express thanks to Congress for supporting FDA. Read More
Analysis and Commentary 10/24/20 Analysis and Commentary 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More
Analysis and Commentary 10/16/20 Analysis and Commentary 10/16/20 Future Changes in Congressional Committees and the FDA Read More
Analysis and Commentary 5/1/20 Analysis and Commentary 5/1/20 No Need for a Crystal Ball in Some Scenarios Read More
Analysis and Commentary 10/30/15 Analysis and Commentary 10/30/15 So ... How Do We Help FDA Get a Fair Cut of the Extra $40 Billion? Read More
